Novartis' heart failure drug serelaxin meets targets PMLiVE A phase III trial of Novartis' serelaxin has met its primary target of reducing shortness of breath in acute heart failure patients, although there is some debate about the clinical significance of the results. Serelaxin is a recombinant form of human ... |
